Taken together, we show that neratinib is a previously unrecognized inhibitor of MST1 and represents a potential β-cell-protective drug with robust proof of concept in vitro in human islets and in vivo in rodent models of both T1D and T2D. The gene discussed is MST1; the disease is type 2 diabetes mellitus.